

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

This announcement is for information purposes only and does not constitute an invitation or offer to acquire, purchase or subscribe for the shares in Alibaba Health Information Technology Limited.



ALIBABA HEALTH INFORMATION TECHNOLOGY LIMITED

阿里健康信息技術有限公司

(Incorporated in Bermuda with limited liability)

(Stock Code: 00241)

GRANT OF RESTRICTED SHARE UNITS

GRANT OF RESTRICTED SHARE UNITS

On March 15, 2024, the Company granted a total of 1,929,300 RSUs to 12 Grantees in accordance with the terms of the Share Award Scheme, subject to acceptance.

This announcement is made pursuant to Rules 17.06A, 17.06B and 17.06C of the Listing Rules.

RESTRICTED SHARE UNITS

On March 15, 2024, the Company granted a total of 1,929,300 RSUs to 12 Grantees in accordance with the terms of the Share Award Scheme, subject to acceptance. The details of the grant of the RSUs are as follows:

Date of Grant : March 15, 2024

Grantees : 12 employees of the Group, none of which are connected persons of the Company

Number of RSUs granted	:	1,929,300	Each of the RSUs granted to the Grantees represents a right to receive a Share on the date the RSU vests
Purchase price for the grant of RSUs	:	Nil	
Closing price of the Shares on the Date of Grant	:	HK\$3.360 per Share	
Vesting period of the RSUs	:	Subject to any alteration by the Company as stated in a separate grant letter between each of the Grantees and the Company, the RSUs granted to the Grantees shall vest over two to four years from the Date of Grant	
Performance targets	:	The RSUs granted are not subject to performance targets	
		Having considered that (i) the grant of RSUs to the Grantees would provide them with the opportunity to acquire equity interests in the Company as recognition of their contribution to the success and development of the Group and (ii) the RSUs vest over a certain time period on a yearly basis which motivates them to remain with, and to strive for the future development and expansion of, the Group and this aligns with the purpose of the Share Award Scheme, the remuneration committee of the Company is of the view that performance targets are not necessary for the RSUs granted to the Grantees	
Clawback mechanism	:	In the event that any circumstances as specified in the respective grant letter arise which include among others, the termination of the Grantee's employment or service by the Company or any of its subsidiaries by reason of the employer terminating the contract of employment without notice or payment in lieu of notice, the Grantee has committed an act of theft, embezzlement, fraud, dishonesty, ethical breach or other similar acts or the commission of a criminal offence or any conduct that is materially adverse to the name, reputation or interests of the Group, the RSUs granted but unvested will automatically lapse in respect of the underlying Shares with effect upon the occurrence of the relevant circumstances	

In relation to the 1,929,300 RSUs granted to the Grantees, new Shares that rank *pari passu* in all respects among themselves and with all the Shares in issue from time to time shall be issued and/or existing Shares in issue to be purchased from the market out of cash contributed by the Company and held on trust for the Grantees shall be transferred to the Grantees (as the case may be) upon vesting and settlement of such RSUs.

REASONS FOR AND BENEFITS OF THE GRANTS

The purpose of the aforesaid grant of the RSUs is to (i) attract skilled and experienced personnel for the further development and expansion of the Group by providing them with the opportunity to acquire equity interests in the Company, (ii) recognize the contribution to the success and development of the Group made by the existing employees of the Group, and/or (iii) generally incentivize and motivate our employees to remain with, and to strive for the future development and expansion of, the Group.

LISTING RULES IMPLICATIONS

To the best of the knowledge of the Directors having made all reasonable enquiries, as at the Date of Grant, (i) none of the Grantees is a Director, chief executive or substantial shareholder of the Company or an associate (as defined under the Listing Rules) of any of them; (ii) none of the Grantees is a participant with Options and the RSUs granted and to be granted exceeding the 1% individual limit under Rule 17.03D(1) of the Listing Rules; (iii) none of the Grantees is a related entity participant or a service provider (as defined under the Listing Rules); and (iv) no financial assistance has been provided by the Group to the Grantees to facilitate the purchase of Shares under the Share Award Scheme. The above grant of the RSUs would not result in the Options and the RSUs granted and to be granted to a Grantee in the 12-month period up to and including the Date of Grant in aggregate to exceed 1% of the Shares in issue.

NUMBER OF SHARES AVAILABLE FOR FUTURE GRANT

Upon the aforesaid grant of the RSUs, 1,340,537,307 Shares underlying the Options and the RSUs are available for future grant under the scheme mandate limit of the Share Award Scheme, and 135,332,785 Shares underlying the Options and the RSUs are available for future grant under the service provider sublimit of the Share Award Scheme.

DEFINITIONS

“Board”	the board of directors of the Company
“Company”	Alibaba Health Information Technology Limited, a company incorporated in Bermuda, the shares of which are listed on the Main Board of the Stock Exchange (stock code: 00241)
“connected person”	has the same meaning ascribed to it under the Listing Rules
“Date of Grant”	March 15, 2024

“Director(s)”	director(s) of the Company
“Grantees”	employees of the Group who are granted RSUs in accordance with the Share Award Scheme on the Date of Grant
“Group”	the Company and its subsidiaries
“HK\$”	Hong Kong dollars, the lawful currency of Hong Kong
“Hong Kong”	Hong Kong Special Administrative Region of the People’s Republic of China
“Listing Rules”	Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited
“Option(s)”	option(s) to subscribe for or acquire Shares which is/are granted under the Share Award Scheme
“RSU(s)”	restricted share unit(s), being a contingent right to receive Share(s) which is/are awarded under the Share Award Scheme
“Share Award Scheme”	the share award scheme adopted by the Company at a special general meeting on November 24, 2014 and amended by the Company at the annual general meeting on August 11, 2023, the principal terms of which were set out in Appendix II to the Company’s circular dated July 14, 2023
“Shares”	ordinary shares of HK\$0.01 each in the issued capital of the Company
“Stock Exchange”	The Stock Exchange of Hong Kong Limited
“subsidiary”	has the same meaning ascribed to it under the Listing Rules

For and on behalf of the Board
Alibaba Health Information Technology Limited
Zhu Shunyan
Chairman

Hong Kong, March 15, 2024

As at the date of this announcement, the Board comprises Mr. Zhu Shunyan, Mr. Shen Difan and Mr. Tu Yanwu as the executive Directors; Ms. Huang Jiaojiao and Mr. Xu Haipeng as the non-executive Directors; and Ms. Huang Yi Fei (Vanessa), Dr. Shao Rong and Ms. Wu May Yihong as the independent non-executive Directors.